| Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.RMD Open | PMID 35654457PMC9163535 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.Lancet Microbe | PMID 35659904无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2.RMD Open | PMID 35701011PMC9198792 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab].Recenti Prog Med | PMID 35758127无 PMCID | 2022-Jun | 0.50 | The abstract describes a randomized, phase III, drug-intervention trial in oncology. However, it does not explicitly report any time-to-event efficacy endpoint (OS, PFS, DFS, HR, or Kaplan-Meier results). The deterministic review also flagged a lack of time-to-event signal. Eligibility cannot be confirmed without explicit efficacy outcome data. | 待处理 |
| DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.J Diabetes | PMID 35762390PMC9366571 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis.Acta Derm Venereol | PMID 35393631PMC9631288 | 2022-May-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: post hoc analysis of a randomized controlled trial.Rheumatology (Oxford) | PMID 34528074PMC9157117 | 2022-May-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).J Clin Psychiatry | PMID 35649167无 PMCID | 2022-May-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections.J Antimicrob Chemother | PMID 35265985无 PMCID | 2022-May-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.Lancet | PMID 35644155无 PMCID | 2022-May-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.N Engl J Med | PMID 35403841PMC9844511 | 2022-May-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.N Engl J Med | PMID 35544369PMC9127699 | 2022-May-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.JAMA | PMID 35608580PMC9131745 | 2022-May-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy - including photon and proton therapy - for the treatment of radioresistant tumors: the ETOILE trial.BMC Cancer | PMID 35606739PMC9128242 | 2022-May-23 | 0.85 | This is a protocol for a Phase III randomized trial in human oncology with a primary time-to-event endpoint (PFS). However, it is excluded because it does not involve a drug-containing intervention (it compares radiotherapy modalities: carbon ions vs. photon/proton therapy) and it presents as a protocol without reported results. | 待处理 |
| Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).J Clin Oncol | PMID 35263150PMC9113208 | 2022-May-20 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.J Clin Oncol | PMID 35420921PMC9113211 | 2022-May-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial.Sci Rep | PMID 35595817PMC9123164 | 2022-May-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values.BMC Cancer | PMID 35596182PMC9123808 | 2022-May-20 | 0.95 | The record describes a health-related quality of life sub-study or analysis from the POLO trial, focusing on reference value derivation and patient-reported outcomes. It does not report on a primary or key secondary time-to-event efficacy endpoint as required. | 待处理 |
| Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.N Engl J Med | PMID 35320659PMC9006787 | 2022-May-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study.Aesthet Surg J | PMID 35092418PMC13267890 | 2022-May-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.Lancet | PMID 35569466PMC9819649 | 2022-May-14 | 0.95 | Meets all eligibility criteria: Phase III, randomized, oncology (prostate cancer), human, drug intervention (ADT), time-to-event primary endpoint (freedom from progression), and reports original final results. | 待处理 |
| Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.Clin Cancer Res | PMID 35247908无 PMCID | 2022-May-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.Blood | PMID 35007321PMC9101248 | 2022-May-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.N Engl J Med | PMID 35544387无 PMCID | 2022-May-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.Nat Commun | PMID 35550508PMC9098894 | 2022-May-12 | 0.70 | The record describes a retrospective biomarker subgroup analysis from a Phase III randomized trial. It does not report a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR for the overall trial population. The outcome analyzed is distant metastasis rate. | 待处理 |
| Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.Lancet | PMID 35378077PMC9077443 | 2022-May-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.Lancet | PMID 35483400无 PMCID | 2022-May-07 | 0.95 | The trial meets criteria for oncology, human, randomized, Phase 3, drug intervention, and original result. However, the primary endpoint is a binary response rate at 6 months, not a time-to-event endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the time_to_event criterion required for inclusion in the Kaplan-Meier digitization cohort. | 待处理 |
| Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.Rheumatology (Oxford) | PMID 34528079PMC9071547 | 2022-May-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial.Rheumatology (Oxford) | PMID 34554243无 PMCID | 2022-May-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.Jpn J Clin Oncol | PMID 35229141PMC9071396 | 2022-May-05 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Two Phase 3 Trials of Baricitinib for Alopecia Areata.N Engl J Med | PMID 35334197无 PMCID | 2022-May-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.Blood | PMID 35511184无 PMCID | 2022-May-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma.Clin Cancer Res | PMID 35190815无 PMCID | 2022-May-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.Clin Cancer Res | PMID 35275991PMC9365376 | 2022-May-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.Dis Colon Rectum | PMID 34890373PMC8985696 | 2022-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.Int J Radiat Oncol Biol Phys | PMID 34986381无 PMCID | 2022-May-01 | 0.95 | The study is a retrospective analysis of the HERA trial focusing on cardiotoxicity (safety) of trastuzumab with radiation therapy. While it is an oncology RCT with a drug intervention, its primary endpoint is cardiotoxicity (LVEF decline and cardiovascular events), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort. | 待处理 |
| Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.J Clin Oncol | PMID 35030011PMC9061149 | 2022-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Is Radiation-Induced Cardiac Toxicity Reversible? Prospective Evaluation of Patients With Breast Cancer Enrolled in a Phase 3 Randomized Controlled Trial.Int J Radiat Oncol Biol Phys | PMID 35085715无 PMCID | 2022-May-01 | 0.85 | The study is a Phase 3 randomized controlled trial in human breast cancer, but the reported outcomes are focused on cardiac perfusion and toxicity (radiation injury), not oncological efficacy (e.g., survival, progression, recurrence). Therefore, it does not meet the outcome criterion for inclusion in an oncology Kaplan-Meier digitization cohort. | 待处理 |
| The Conventional Technique Versus the No-touch Isolation Technique for Primary Tumor Resection in Patients With Colon Cancer (JCOG1006): A Multicenter, Open-label, Randomized, Phase III Trial.Ann Surg | PMID 35129519无 PMCID | 2022-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 35238873PMC8895313 | 2022-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage: A Substudy of a Randomized Clinical Trial.JAMA Neurol | PMID 35311937PMC8938900 | 2022-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 35323856PMC8949760 | 2022-May-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.JAMA Oncol | PMID 35357396PMC8972152 | 2022-May-01 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.Allergy Asthma Proc | PMID 35524357无 PMCID | 2022-May-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.J Dermatolog Treat | PMID 33222559无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.Arthritis Care Res (Hoboken) | PMID 33227175无 PMCID | 2022-May | 0.95 | The study is a Phase III randomized trial of a drug (secukinumab) in humans, but it is not an oncology study (ankylosing spondylitis) and does not have a time-to-event efficacy endpoint (e.g., OS, PFS). The primary outcome is a patient-reported fatigue scale (FACIT-F). | 待处理 |
| Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.J Dermatolog Treat | PMID 33678106无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.J Dermatolog Treat | PMID 33896356无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of duloxetine in patients with knee osteoarthritis or chronic low back pain with early pain reduction: An exploratory post-hoc analysis of Japanese phase 3, 1-year extension studies.J Orthop Sci | PMID 33958268无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study.Clin Exp Rheumatol | PMID 34251303无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |